Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why DexCom (DXCM) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

DexCom Q3 Earnings Beat Estimates on Sensor Growth, Stock Rises

by Zacks Equity Research

DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.

DexCom (DXCM) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 4.65% and 0.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?

by Zacks Equity Research

DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.

Analysts Estimate Inari Medical, Inc. (NARI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Inari Medical (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stay Ahead of the Game With DexCom (DXCM) Q3 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Earnings Preview: DexCom (DXCM) Q3 Earnings Expected to Decline

by Zacks Equity Research

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Retain DexCom Stock in Your Portfolio for Now

by Zacks Equity Research

DXCM continues to raise optimism among investors, owing to its strong product portfolio.

Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe

by Zacks Equity Research

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.

DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

by Zacks Equity Research

DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.

DexCom's (DXCM) G7 CGM Coverage Expanded for Quebec Residents

by Zacks Equity Research

DexCom (DXCM) announces that Quebec residents aged two years and older living with type 1 diabetes may now be eligible to receive coverage for Dexcom G7.

Medtronic (MDT) Progresses in CGM With New Approval, Alliance

by Zacks Equity Research

The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.

Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity

by Zacks Equity Research

The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.

DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.

DexCom (DXCM) Q2 Earnings Surpass Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 10.26% and 3.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.

IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

IQVIA (IQV) delivered earnings and revenue surprises of 2.33% and 0.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

AMN Healthcare (AMN) Unveils ShiftWise Flex Manager Hub App

by Zacks Equity Research

AMN Healthcare's (AMN) Manager Hub app, part of the ShiftWise Flex platform, revolutionizes workforce management for healthcare organizations with enhanced mobile capabilities and comprehensive insights.

BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage

by Zacks Equity Research

BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.

How to Play Intuitive Surgical (ISRG) Ahead of Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific

by Zacks Equity Research

DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.

Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results

by Zacks Equity Research

Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.

Here's Why DexCom (DXCM) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.